Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
Completed
UCB Pharma
Phase 4
2005-10-01
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in
symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective
Serotonin Reuptake Inhibitor (SSRI)or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
to that in subjects treated with a newly prescribed SSRI/SNRI alone. Subjects must be at
least 18 years of age and positive for Generalized Anxiety Disorder (GAD)or Panic Disorder.
Subjects will be randomized to receive concomitant Niravam™ and an SSRI/SNRI or an SSRI/SNRI
alone during the study. Most symptom evaluations will be done using an automated phone
interview system. There are 4 clinic visits.
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions
Completed
Actavis Inc.
Phase 1
2006-06-01
This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam
Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2
mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs
Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult
volunteers administered under fasting conditions.
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions
Completed
Actavis Inc.
Phase 1
2006-07-01
This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam
Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2
mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs
Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult
volunteers administered under non-fasting conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
